Sign In
Buy ASND
$216.79
+0.190 (+0.0877%)
At Close: Jun 03, 2026
BioMarin Pharmaceutical (BMRN) Receives a Buy from Canaccord Genuity
10:12am, Friday, 01'st May 2020
In a report issued on April 27,
Michelle Gilson
from Canaccord Genuity maintained a
Buy
rating on BioMarin Pharmaceutical (
BMRN
–
Research Report
), with a price target of
$108.00
. The company’s
Analysts Offer Insights on Healthcare Companies: SLANG Worldwide (OtherSLGWF), Stryker (SYK) and BioMarin Pharmaceutical (BMRN)
10:07am, Friday, 01'st May 2020
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on SLANG Worldwide (SLGWF), Stryker (SYK) and BioMarin
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on SLANG Worldwide
Ascendis Pharma A/S (NASDAQ:ASND) Lowered to Hold at BidaskClub
08:54am, Tuesday, 28'th Apr 2020
Ascendis Pharma A/S (NASDAQ:ASND) was downgraded by stock analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Tuesday, BidAskClub reports. Several other
Best & Worst ADRs - Monday, April 27
04:04pm, Monday, 27'th Apr 2020
The top-ranked sectors are healthcare, technology, consumer goods, and utilities.
Geode Capital Management LLC Increases Position in Ascendis Pharma A/S (NASDAQ:ASND)
09:22am, Monday, 27'th Apr 2020
Geode Capital Management LLC increased its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 0.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exc
Altium Wealth Management LLC Invests $259,000 in Ascendis Pharma A/S (NASDAQ:ASND)
10:42am, Saturday, 25'th Apr 2020
Altium Wealth Management LLC acquired a new stake in Ascendis Pharma A/S (NASDAQ:ASND) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC
SVB Leerink Analysts Reduce Earnings Estimates for Ascendis Pharma A/S (NASDAQ:ASND)
06:06am, Friday, 24'th Apr 2020
Ascendis Pharma A/S (NASDAQ:ASND) – Stock analysts at SVB Leerink decreased their Q1 2020 EPS estimates for Ascendis Pharma A/S in a research report issued to clients and investors on Monday, April
Ascendis Pharma A/S (NASDAQ:ASND) PT Raised to $201.00
08:24am, Wednesday, 22'nd Apr 2020
Ascendis Pharma A/S (NASDAQ:ASND) had its price target hoisted by equities research analysts at Cantor Fitzgerald from $185.00 to $201.00 in a research report issued on Monday, MarketBeat reports. The
Ascendis Pharma A/S (NASDAQ:ASND) PT Raised to $171.00
07:50am, Wednesday, 22'nd Apr 2020
Ascendis Pharma A/S (NASDAQ:ASND) had its target price hoisted by stock analysts at Stifel Nicolaus from $146.00 to $171.00 in a research report issued on Monday, The Fly reports. The brokerage curren
Oppenheimer Boosts Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $219.00
07:50am, Wednesday, 22'nd Apr 2020
Ascendis Pharma A/S (NASDAQ:ASND) had its price objective lifted by analysts at Oppenheimer from $199.00 to $219.00 in a report released on Monday, The Fly reports. The firm presently has an “outper
JPMorgan Chase & Co. Increases Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $150.00
07:18am, Wednesday, 22'nd Apr 2020
Ascendis Pharma A/S (NASDAQ:ASND) had its price target raised by stock analysts at JPMorgan Chase & Co. from $145.00 to $150.00 in a note issued to investors on Monday, The Fly reports. The firm prese
Biofrontera's New Deal, And Other News: The Good, Bad And Ugly Of Biopharma
05:16am, Wednesday, 22'nd Apr 2020
Biofrontera inks a new deal and announces earnings. Ascendis reports top line data from TransCon trial. Precigen will start a phase 2/3 trial in HPV.
Need To Know: The Consensus Just Cut Its Ascendis Pharma A/S (NASDAQ:ASND) Estimates For 2020
10:12am, Tuesday, 21'st Apr 2020
The latest analyst coverage could presage a bad day for Ascendis Pharma A/S (NASDAQ:ASND), with the analysts making...
Ascendis Pharma A/S (NASDAQ:ASND) Analysts Just Slashed This Year's Revenue Estimates By 12%
10:01am, Tuesday, 21'st Apr 2020
Market forces rained on the parade of Ascendis Pharma A/S (NASDAQ:ASND) shareholders today, when the analysts...
